Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma: Results from a Phase II Multicenter Study

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1299-1305

  Pless, Miklos ^a   Belhadj, Karim ^b   Menssen, Hans D ^c   Kern, Wolfgang ^d   Coiffier, Bertrand ^e   Wolf, Jürgen ^f   Herrmann, Richard ^a   Thiel, Eckhard ^c   Bootle, Doug ^g   Sklenar, Ivo ^g   Müller, Christian ^g   Choi, Les ^g   Porter, Carl ^h   Capdeville, Renaud ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HENRI MONDOR HOSPITAL   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^g NOVARTIS PHARMA AG   (Switzerland)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; MITOGUAZONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; POLYAMINE; PREDNISONE; RITUXIMAB; SAM 486A; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUSHING; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOPENIA; LUNG EMBOLISM; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POLYAMINE SYNTHESIS; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SINUS ARRHYTHMIA; SUPRAVENTRICULAR TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ADENOSYLMETHIONINE DECARBOXYLASE; ADULT; AGED; AGED, 80 AND OVER; AMIDINES; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYAMINES; PROGNOSIS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 12144288924     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0977-03     Document Type: Article

References (34)

1. Porter, C. W., Regenass, U., and Bergeron, R. J. Polyamine inhibitors and analogues as potential anticancer agents. In: R. H. Dowling, U. R. Foelsch, and R. Loeser (eds.), Polyamines in the Gastrointestinal Tract, Ed. 62, pp. 301-322. Dordrecht: Kluwer Academic Publishers, 1992.
2. Pegg, A. E. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res., 48: 759-774, 1988.
3. Porter, C. W., and Sufrin, J. R. Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential anticancer chemotherapeutic strategy. Anticancer Res, 6: 525-542, 1986.
4. Warrell, R. P., Jr., and Burchenal, J. H. Methylglyoxal-bis(guanyl-hydrazone) (Methyl-GAG): current status and future prospects. J. Clin. Oncol., 1: 52-65, 1983.
5. Kramer, D., Mett, H., Evans, A., Regenass, U., Diegelman, P., and Porter, C. W. Stable amplification of the S-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J. Biol. Chem., 270: 2124-2132, 1995.
6. Warrell, R. P., Jr., Lee, B. J., Kempin, S. J., Lacher, M. J., Straus, D. J., and Young, C. W. Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma. Blood, 57: 1011-1014, 1981.
7. Kuhn, J. G., Knight, W. A., III, and McDaniel, T. M. Methylglyoaxal bis (guanylhydrazone) (Methyle-GAG) in the management of non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol., 1: 163a, 1982.
8. Knight, W. A., III, Fabian, C., Costanzi, J. J., Jones, S. E., and Coltman, C. A., Jr. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group. Investig. New Drugs, 1: 235-237, 1983.
9. Levine, A. M., Tulpule, A., Tessman, D., Kaplan, L., Giles, F., Luskey, B. D., Scadden, D. T., Northfelt, D. W., Silverberg, I., Wernz, J., Espina, B., and Von Hoff, D. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J. Clin. Oncol., 15: 1094-1103, 1997.
10. Pine, M. J., and DiPaolo, J. A. The antimitochondrial action of 2-choloro-4′, 4"-bis(2-imidazolin-2-yl)terephthalanilide and methylglyoxal bis(guanylhydrazone). Cancer Res., 26: 18-25, 1966.
11. Dorhout, B., te Velde, R. J., Ferwerda, H., Kingma, A. W., de Hoog, E., and Muskiet, F. A. In vivo effects of 4-amidinoindan-1-one 2′ -amidinohydrazone (CGP 48664A) and alpha-difluoromethylomithine (DFMO) on L1210 growth, cell-cycle phase distribution and polyamine contents. Int. J. Cancer, 62: 738-742, 1995.
12. Dorhout, B., Te Velde, R. J., Ferwerda, H., Kingma, A. W., De Hoog, E., and Muskiet, F. A. In vivo growth inhibition of L1210 leukemia by 4-amidinoindan-1-one 2′-amidinohydrazone (CGP 48664A), a new inhibitor of S-adenosylmethionine decarboxylase. Int. J. Cancer, 61: 214-217, 1995.
13. Eskens, F. A., Greim, G. A., van Zuylen, C., Wolff, I., Denis, L. J., Planting, A. S., Muskiet, F. A., Wanders, J., Barbet, N. C., Choi, L., Capdeville, R., Verweij, J., Hanauske, A. R., and Bruntsch, U. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Clin. Cancer Res., 6: 1736-1743, 2000.
14. Paridaens, R., Uges, D. R., Barbet, N., Choi, L., Seeghers, M., van der Graaf, W. T., Groen, H. J., Dumez, H., Buuren, I. V., Muskiet, F., Capdeville, R., Oosterom, A. T., and de Vries, E. G. A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br. J. Cancer, 83: 594-601, 2000.
15. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Investig. New Drugs, 10: 239-253, 1992.
16. Gordon, L. I., Harrington, D., Andersen, J., Colgan, J., Glick, J., Neiman, R., Mann, R., Resnick, G. D., Barcos, M., Gottlieb, A., et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N. Engl. J. Med., 327: 1342-1349, 1992.
17. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med., 329: 987-994, 1993.
18. Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials, 10: 1-10, 1989.
19. Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., Jr., and Miller, T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med., 328: 1002-1006, 1993.
20. Miller, T. P., Dahlberg, S., Cassady, J. R., Adelstein, D. J., Spier, C. M., Grogan, T. M., LeBlanc, M., Carlin, S., Chase, E., and Fisher, R. I. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N. Engl. J. Med., 339: 21-26, 1998.
21. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., and Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med., 346: 235-242, 2002.
22. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J. A., Capdeville, R., Diehl, V., and Reyes, F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92: 1927-1932, 1998.
23. Onrust, S. V., Lamb, H. M., and Balfour, J. A. Rituximab. Drugs, 58: 79-88; discussion 89-90, 1999.
24. Kimby, E., Brandt, L., Nygren, P., and Glimelius, B. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol., 40: 198-212, 2001.
25. Dumontet, C., Morschhauser, F., Solal-Celigny, P., Bouafia, F., Bourgeois, E., Thieblemont, C., Leleu, X., Hequet, O., Salles, G., and Coiffier, B. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br. J. Haematol., 113: 772-778, 2001.
26. Savage, D. G., Rule, S. A., Tighe, M., Garrett, T. J., Oster, M. W., Lee, R. T., Ruiz, J., Heitjan, D., Keohan, M. L., Flamm, M., and Johnson, S. A. Gemcitabine for relapsed or resistant lymphoma. Ann. Oncol., 11: 595-597, 2000.
27. Fossa, A., Santoro, A., Hiddemann, W., Truemper, L., Niederle, N., Buksmaui, S., Bonadonna, G., Seeber, S., and Nowrousian, M. R. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol., 17: 3786-3792, 1999.
28. Crump, M., Couban, S., Meyer, R., Rudinskas, L., Zanke, B., Gluck, S., Maksymiuk, A., Hoskins, P., Matthews, S., and Eisenhauer, E. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk. Lymphoma, 43: 1581-1587, 2002.
29. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., and Levy, R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol., 18: 3135-3143, 2000.
30. Germann, N., Brienza, S., Rotarski, M., Emile, J. F., Di Palma, M., Musset, M., Reynes, M., Soulie, P., Cvitkovic, E., and Misset, J. L. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann. Oncol., 10: 351-354, 1999.
31. Weidmann, E., Kim, S. Z., Rost, A., Schuppert, H., Seipelt, G., Hoelzer, D., and Mitrou, P. S. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann. Oncol., 13: 1285-1289, 2002.
32. Sarris, A. H., Psyrri, A., Hagemeister, F., Romaguera, J., McLaughlin, P., Rodriguez, M. A., Bachier, C., Younes, A., Mesina, O., Oholendt, M., Medeiros, L. J., Samuels, B., Adams, L. M., and Cabanillas, F. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk. Lymphoma, 39: 291-299, 2000.
33. Casasnovas, R. O., Haioun, C., Dumontet, C., Gabarre, J., Richard, B., Lederlin, P., Caillot, D., Stamatoullas, A., Morel, P., Quesnel, B., Blay, J. Y., Bouabdallah, K., and Gisselbrecht, C. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica, 85: 502-507, 2000.
34. Siu, L. L., Rowinsky, E. K., Hammond, L. A., Weiss, G. R., Hidalgo, M., Clark, G. M., Moczygemba, J., Choi, L., Linnartz, R., Barbet, N. C., Sklenar, I. T., Capdeville, R., Gan, G., Porter, C. W., Von Hoff, D. D., and Eckhardt, S. G. A Phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-3-week schedule in patients with advanced solid malignancies. Clin. Cancer Res., 8: 2157-2166, 2002.